Extensive prophylactic central and lateral neck lymph-node compartment dissections for patients with papillary thyroid cancers smaller than 2 cm modifies the indication for $^{131}$I therapy


SUMMARY

BACKGROUND Prophylactic cervical lymph-node dissection denotes removal of lymph nodes that are considered normal preoperatively or intraoperatively, and therapeutic dissection refers to removal of malignant lymph nodes identified before or during surgery. Although some advocate routine prophylactic cervical-lymph-node central-compartment dissection for patients with papillary thyroid cancer (PTC), this remains controversial. The aim of this retrospective study was to quantify the role of prophylactic central and lateral neck lymph-node compartment dissection, and to describe its role in staging small tumors and treating them with $^{131}$I.

METHODS Patients selected for study had PTCs 1 to 1.9 cm designated as stage T1N0 according to the 6th edition of the American Joint Commission on Cancer (AJCC) TNM classification (T denotes tumor; N lymph node, and M distant metastases [https://www.protocols.fccc.edu/fccc/pims/staging/thyroid.html]).

All had negative results on neck ultrasonography preoperatively and had total thyroidectomy, prophylactic bilateral level VI, and ipsilateral level III and IV cervical-lymph-node compartment dissections (Figure 1) that were extended to levels II and V when tumor was found in the superior pole of the thyroid or when metastases were found in level III or IV. Radioiodine therapy was not administered when a patient had no adverse prognostic factors such as lymph-node metastases, no tumor extension beyond the thyroid capsule, vascular invasion, unfavorable histology such as tall-cell carcinoma, or T1 <10-mm tumors with lymph-node micrometastases or when the patient was 18 years of age or younger. The others were treated with 30 to 100 mCi of $^{131}$I (1.1 to 3.7 GBq) after levothyroxine withdrawal or recombinant human thyrotropin (rhTSH) administration. All patients had follow-up for at least 1 year. Paralysis of the recurrent laryngeal nerve or hypoparathyroidism was considered permanent if it persisted for longer than 1 year. A serum thyroglobulin (Tg) ≤0.9 ng/ml was considered undetectable.

RESULTS A total of 115 patients were studied (99 women [86%], 16 men [14%]; mean age, 48.5 years; range, 18 to 73 years; median, 50 years). Mean PTC size was 13.1 mm (range, 1-19) on ultrasound and 12.5 mm (range, 1 to 19) on final pathology, and was smaller than 10 mm in 51 patients (44%). The tumor was unifocal in 73 patients (64%), multifocal and bilateral in 25 (22%), and multifocal but unilateral in 17 (15%), extended beyond the thyroid capsule (pT3) in 33 (29%), and showed vascular invasion in 7 (6%) (Figure 2). Two had diffuse sclerosing variant PTC. Bilateral prophylactic central neck dissection was performed in all of the patients; prophylactic ipsilateral dissections were performed in 96 (94%) and bilateral level III-IV dissections were performed in 6 (6%). Ipsilateral level III-IV-V dissections were performed in 13 patients, 10 of whom (77%) had ipsilateral and 3 (23%) bilateral tumors (Figure 3). The mean number of central lymph nodes dissected per patient was 12 (range, 2 to 26; median, 7) and the mean number of lymph nodes per patient was 5 (range, 1 to 11; median, 2). Among the metastatic lymph nodes, 14.8% had extracapsular extension. The.
Univariate analysis identified the following prognostic factors for lymph-node involvement: age younger than 50 years (P = 0.001) and tumor extension beyond the thyroid capsule (P = 0.031), but multivariate analysis identified only age (odds ratio, 5.657; P < 0.001) and tumor extension (odds ratio, 2.477; P = 0.48) as significant factors for lymph-node metastases.

In all, 48 patients (42%) were not treated with $^{131}$I. Of this group, 44 (92%) had no lymph-node metastases or adverse prognostic factors, which included 31 tumors <10 mm and 13 >10 mm; 4 had a PTC <10 mm with micrometastases (Figure 5). In all, 67 patients (58%) had $^{131}$I therapy for the following adverse prognosis factors: lymph-node metastases in 44 patients (38%), PTC >18 mm in 12 (10%), tumor extension beyond the thyroid capsule in 6 (5%), vascular invasion in 2 (2%), diffuse sclerosing variant of PTC in 1 (0.9%), and age <18 years in 2 (2%). Using the European consensus recommendations, lymph-node status modified the decision for postsurgical $^{131}$I ablation for 25 of 115 patients (21.7%), 13 with T >10 mm and 12 with T <10 mm. Excluding the 33 patients with pT3 tumors, the indication for $^{131}$I remnant ablation was modified in 25 of 82 patients (30.5%) with pT1 tumors. On the posttreatment whole-body scan, 59 patients (51%) had foci of $^{131}$I uptake in the thyroid bed thought to be thyroid remnant. Radioiodine uptake was found in the central neck in 2 patients and in the lateral neck in 6, 1 of whom also had diffuse lung uptake.

One year after surgery, 1 patient (0.9%) had persistent laryngeal palsy and another (0.9%) had persistent hypoparathyroidism; no patients had suspicious cervical lymph nodes on ultrasound. Serum Tg levels during thyroid hormone suppression or rhTSH stimulation levels of Tg was undetectable ($\leq 0.9 \mu$IU/ml) on levothyroxine or after rhTSH stimulation in 97% of patients who had been treated postoperatively with $^{131}$I.

**CONCLUSION**
Prophylactic central and ipsilateral lateral neck dissection for PTC smaller than 2 cm facilitates the accurate selection of patients for $^{131}$I ablation and modifies the indication for $^{131}$I in 30% of patients with T1 tumors.
COMMENTARY

Slow growth and a favorable prognosis for survival characterize the clinical behavior of small PTCs with regional lymph-node metastases; however, the major challenge is to control locoregional recurrence, which happens with surprisingly high frequency. The rates of PTC lymph-node metastases in both low- and high-risk patients range from 25% to 60%, depending on the extent of surgery (1-3). Although lymph-node metastases are widely regarded to increase local recurrence rates without affecting survival, several studies suggest otherwise. A study of prophylactic lymph-node dissection in 342 patients with PTC found that systematic compartment-oriented dissection of lymph-node metastases improved recurrence (P<0.0001) and survival (P<0.005) especially in patients with T1 to T3 tumors (AJCC) (4). A study of almost 10,000 patient records maintained in the Surveillance, Epidemiology, and End Results (SEER) registry found that 14-year survival of patients with and without lymph-node metastases was 82% and 79%, respectively (P<0.05)(5). A more recent study (6) of the SEER registry records of 33,088 patients found that lymph-node metastases in patients 45 years or older with PTC, and patients of all ages with follicular thyroid cancer were associated with a 46% increased risk of death (P<0.001).

The ATA guidelines under revision suggest that prophylactic central-compartment neck dissection (ipsilateral or bilateral) may be performed in patients with PTC with clinically uninvolved central neck lymph nodes, especially for advanced primary tumors (T3 or T4), which is a Grade C recommendation (Expert Opinion), and that near-total or total thyroidectomy without prophylactic central neck dissection may be appropriate for small (T1 or T2) noninvasive clinically node-negative PTCs and most follicular cancers (Grade C recommendation). The ATA guidelines also suggest preoperative cervical ultrasonography in all patients undergoing thyroidectomy. Although ultrasonography may identify suspicious cervical lymphadenopathy in up to half the cases, potentially altering the surgical approach in many patients, it has serious limitations in evaluating extracapsular invasion of the thyroid in deep locations in the neck and lymph-node metastasis in the central neck, which may lower the sensitivity of ultrasonography as much as 35% (7). There is controversy about prophylactic lymph-node dissections, especially in lymph-node compartment level VI. A systematic review of central lymph-node dissection by White et al. (8) found that systematic compartment-oriented central lymph-node dissection may decrease recurrence of PTC and likely improves disease-specific survival (Grade C recommendation) and that adding central lymph-node dissection to total thyroidectomy can significantly reduce serum Tg levels. They also concluded that there may be a higher rate of permanent hypoparathyroidism and unintentional permanent laryngeal nerve injury when compartment-oriented central lymph-node dissection is performed. Further, reoperation in the central neck compartment for recurrent PTC may increase the risk for hypoparathyroidism and unintentional nerve injury as compared with total thyroidectomy with or without central lymph-node dissection (Grade C recommendation) supporting a more aggressive initial operation (12).

The Bonnet study is a remarkable contribution that shows how meticulous lymph-node compartment dissection provides explicit information about initial tumor stage, which was far greater than T1N0 in a number of cases. The findings at surgery modified the decision for remnant ablation in 30% of the patients. No 131I was administered to 42% of the patients, and 58% were treated with 131I. The tumor was found to be unifocal in 64%, multifocal and bilateral in 22% and multifocal but unilateral in 17 (15%), and extended beyond the thyroid capsule (pT3) in 29%, and showed vascular invasion in 6%. None of this was suspected preoperatively. Prophylactic dissection resulted in unambiguous 131I treatment of patients with lymph-node metastases while forgoing 131I therapy for those without residual locoregional tumor. Whether patients will accept such extensive surgery for what is traditionally thought to be low-risk tumor remains to be seen.

Another important matter is that surgeons may not embrace this approach, as it likely prolongs the operative time for thyroidectomy. The surprising thing, however, is how prophylactic compartment dissection remarkably changed the stage of the disease, as compared with preoperative ultrasonography. Advocates of postsurgical radiation should recognize that the Bonnet study points the way to accurate selection of patients for 131I therapy after surgery when tumors are metastatic or invasive.

Ernest L. Mazzaferri, MD MACP

References